| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CZOL446HTW06 |
| Title of Study |
A prospective study to evaluate the safety and efficacy of Aclasta® (Zoledronic acid) in the treatment of osteoporosis in postmenopausal women |
| Primary Objective |
The primary objective is to evaluate safety of zoledronic acid in postmenopausal patients with osteoporosis. Safety assessment : To evaluate the incidence of adverse events. |
| Number of Sites |
15 |
| Period of Study |
from 2009-09-15 to 2012-11-15 |
| Number of Patients |
800 |
| IRB Approval Date |
04-Aug-2009 |
| Publication Plan / Date |
15-Nov-2013 |
